The CRISPR-Cas system is often described as "molecular scissors," but this analogy misses a crucial mechanical constraint. Before these scissors can cut, they must first "dock" onto a specific short sequence of DNA known as the Protospacer Adjacent Motif (PAM).
For the most common tool, Streptococcus pyogenes Cas9 (SpCas9), this docking sequence is "NGG." If a target gene or a specific disease-causing mutation does not happen to sit immediately next to an NGG motif, the enzyme is effectively blind to it. This requirement creates significant "blind spots" across the genome, restricting our ability to image, edit, or regulate DNA at will.
Research in this field is focused on breaking these sequence constraints to achieve universal genomic accessibility—the ability to target any single base pair in any organism.
The Docking Problem and Genomic Blind Spots
The PAM acts as a physical license plate that the Cas enzyme must verify before it is allowed to unzip the DNA and check if the guide RNA matches the target. As Baohui Chen and Juan Guan explain in Imaging Specific Genomic DNA in Living Cells, this constraint is particularly frustrating for live-cell imaging, where probes must be placed at high density to visualize chromosomal dynamics. If the PAMs aren't there, the picture remains blurry.
This limitation extends to therapeutics. In Harnessing the evolving CRISPR/Cas9 for precision oncology, Shuiquan Li and colleagues note that many oncogenic mutations are "un-editable" simply because they lack a nearby NGG motif. To move toward personalized medicine, the "scissors" must become sequence-agnostic.
Expanding the Toolbox with Natural Orthologs
The first strategy to overcome this was to look at how other bacteria solved the problem. Different species evolved Cas enzymes that recognize different PAMs.
Bernd Zetsche, Feng Zhang, and their team screened 16 uncharacterized Cas12a orthologs in A Survey of Genome Editing Activity for 16 Cas12a Orthologs, identifying variants like Mb3Cas12a that recognize a relaxed "TTN" PAM. While Cas9 prefers G-rich regions, Cas12a opens up T-rich regions of the genome. This is particularly useful in plants; Chong Ren demonstrated in Efficient genome editing in grapevine using CRISPR/LbCas12a system that Cas12a can rewire metabolic pathways in grapes by targeting regions Cas9 cannot reach.
Engineering PAM Flexibility
Rather than just finding new enzymes, researchers began re-engineering the PAM-interacting domain (PID) of existing ones. The goal is to make the "docking pocket" more promiscuous or change its preference entirely.
- AT-Rich Targeting: Jooyoung Lee and Joseph M. Jacobson engineered iSpyMac, a variant that recognizes adenine dinucleotides (NAAN), opening up nearly 20% of the human genome that was previously inaccessible to standard Cas9 (A Cas9 with PAM recognition for adenine dinucleotides).
- Broad Recognition: Jingtong Liu identified SeqCas9, which recognizes a highly flexible "NNG" PAM, combining broad targeting with the high specificity required for clinical use (Enhanced genome editing with a Streptococcus equinus Cas9).
- Structural Insights: To understand why some enzymes are naturally more flexible, Omar Abudayyeh and Jonathan S. Gootenberg solved the structure of CdCas9. They found it uses a unique "greasy" hydrophobic patch to interact with DNA, providing a blueprint for how to design more promiscuous binders (Structural basis for the promiscuous PAM recognition by Corynebacterium diphtheriae Cas9).
The Trade-off Between Flexibility and Efficiency
Engineering a "universal" Cas9 is not without costs. In a large-scale competition between PAM-flexible variants like xCas9 and Cas9-NG, Mateusz Legut and Neville Sanjana's team found that while these variants can target more sites, they are often less efficient at cutting than the wild-type enzyme (High-throughput screens of PAM-flexible Cas9 variants for gene knock-out and transcriptional modulation).
However, for applications like Matrix Regulation, where the goal is to fine-tune gene expression rather than cut DNA, this trade-off is acceptable. Xiaohong Teng and Zibai Wang used NG-recognizing variants to precisely position regulatory proteins in yeast promoters, achieving massive increases in chemical production (Matrix regulation: a plug-and-tune method for combinatorial regulation in Saccharomyces cerevisiae).
Toward PAM-less Systems and Universal Access
The ultimate evolution of this direction is the creation of chimeric or "PAM-less" systems. The PAM-flexible genome editing with an engineered chimeric Cas9 paper describes SpRYc, a hybrid enzyme that offers near-universal genomic accessibility by combining the strengths of multiple engineered variants.
In the realm of diagnostics, the PAM requirement can be bypassed entirely. Yizhen Liu and colleagues discovered that LbuCas13a, an enzyme usually reserved for RNA, can target DNA with extreme specificity without needing a PAM at all (From RNA to DNA: CRISPR/LbuCas13a Demonstrates Exceptional Single-Nucleotide Specificity). This allows for the detection of pathogens or mutations in any sequence context, a feat Robert Greensmith and Cristian V. Riella leveraged to create rapid, point-of-care genotyping for kidney disease (CRISPR-enabled point-of-care genotyping for APOL1 genetic risk assessment).
By systematically relaxing and eventually removing the PAM requirement, researchers are transforming CRISPR from a tool that works "wherever there is an NGG" into a truly universal platform for reading and writing the code of life.